Published: Jeffrey Cummings

Dr. Jeffrey Cummings (Brain Health) recently published an article outlining a novel method for determining whether Alzheimer’s drug treatments in clinical trials are ready to move on to the next phase. The paper, “Translational Scoring of Candidate Treatments for Alzheimer’s Disease: A Systematic Approach,” was published in The Journal of Dementia and Geriatric Cognitive Disorder

With an estimated 99 percent of drugs in the development pipeline failing, Cummings outlines a semi-qualitative scoring method designed to help identify deficiencies with the goal of decreasing the failure rate and helping bring new therapies to Alzheimer’s patients. His analysis shows that each drug can be analyzed in five critical areas and scored on a scale of 1-5 for a maximum of 25. A drug with a score closer to 25 would be ready for the next phase. Currently, drugs that are moved ahead despite a low score are at a high risk for failure.

People in the News

A man stands next to a stone wall
People | October 22, 2020
Outstanding Alumnus of the Year didn't let a little thing like Nevada's only law school closing stop him from pursuing a legal education.
A man leands against a wall with his arms folded
People | October 21, 2020
Silver State Award-winner Larry Ruvo is still charging hard into philanthropy, just like he has for more than 40 years.
woman in doctor's coat
People | October 21, 2020
Experiencing a sports injury in high school prompted Laura Wozniak to change career paths.